MRI FOR PRE-DEMENTIA TRIALS
G.B. Frisoni, M. Boccardi
J Prev Alz Dis 2016;3(1):5-7
Structural magnetic resonance imaging (MRI) provides valid markers of whole brain and regional areas of atrophy in Alzheimer’s disease (AD), which are sensitive to change and correlate with clinical progression. Recent efforts to develop standardized and harmonized protocols for MRI indicate high measurement stability and good reproducibility, supporting the use of these measures in clinical trials. Newer MRI measures of microstructural and connectivity changes are also showing promise as early stage biomarkers of neurodegeneration and potentially as measures of treatment effects. Further work is needed to validate these markers for use in clinical trials.
G.B. Frisoni ; M. Boccardi (2015): MRI for Pre-Dementia Trials . The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2015.69